Literature DB >> 17242153

Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis.

Elisabetta Iona1, Federico Giannoni, Manuela Pardini, Lara Brunori, Graziella Orefici, Lanfranco Fattorini.   

Abstract

Long-term nonreplicating (dormant) Mycobacterium tuberculosis populations (26-day-old cells) were sterilized by metronidazole plus rifampin, but not by metronidazole or rifampin alone, after 7 and 11 days of exposure to the drugs. Lower or no drug activity was observed against 19- or 12-day-old dormant or 5-day-old actively replicating populations.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17242153      PMCID： PMC1855463          DOI： 10.1128/AAC.01468-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Metronidazole therapy in mice infected with tuberculosis.

Authors:  J V Brooks; S K Furney; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  New insights into the function of granulomas in human tuberculosis.

Authors:  Timo Ulrichs; Stefan H E Kaufmann
Journal:  J Pathol       Date:  2006-01       Impact factor: 7.996

3.  In Vitro Model of Hypoxically Induced Nonreplicating Persistence of Mycobacterium tuberculosis.

Authors:  L G Wayne
Journal:  Methods Mol Med       Date:  2001

4.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

Review 5.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 6.  Tuberculosis - metabolism and respiration in the absence of growth.

Authors:  Helena I M Boshoff; Clifton E Barry
Journal:  Nat Rev Microbiol       Date:  2005-01       Impact factor: 60.633

Review 7.  M. tuberculosis persistence, latency, and drug tolerance.

Authors:  James E Gomez; John D McKinney
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

8.  Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis.

Authors:  C N Paramasivan; G Kubendiran; D Herbert
Journal:  Indian J Med Res       Date:  1998-10       Impact factor: 2.375

9.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.

Authors:  L G Wayne; H A Sramek
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Metronidazole has no antibacterial effect in Cornell model murine tuberculosis.

Authors:  J Dhillon; B W Allen; Y M Hu; A R Coates; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  1998-09       Impact factor: 2.373
View more
  9 in total

1.  Activity of drug combinations against dormant Mycobacterium tuberculosis.

Authors:  Perla Filippini; Elisabetta Iona; Giovanni Piccaro; Pascale Peyron; Olivier Neyrolles; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

2.  Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.

Authors:  Joy Debnath; Shajila Siricilla; Bajoie Wan; Dean C Crick; Anne J Lenaerts; Scott G Franzblau; Michio Kurosu
Journal:  J Med Chem       Date:  2012-04-06       Impact factor: 7.446

3.  Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.

Authors:  Giovanni Piccaro; Federico Giannoni; Perla Filippini; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

Review 4.  New drugs and regimens for treatment of TB.

Authors:  Eric Leibert; William N Rom
Journal:  Expert Rev Anti Infect Ther       Date:  2010-07       Impact factor: 5.091

5.  MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis.

Authors:  Michio Kurosu; Dean C Crick
Journal:  Med Chem       Date:  2009-03       Impact factor: 2.745

6.  Measuring of Mycobacterium tuberculosis growth. A correlation of the optical measurements with colony forming units.

Authors:  Katia Peñuelas-Urquides; Licet Villarreal-Treviño; Beatriz Silva-Ramírez; Liliana Rivadeneyra-Espinoza; Salvador Said-Fernández; Mario Bermúdez de León
Journal:  Braz J Microbiol       Date:  2013-05-31       Impact factor: 2.476

7.  C-terminal intrinsically disordered region-dependent organization of the mycobacterial genome by a histone-like protein.

Authors:  Anna Savitskaya; Akihito Nishiyama; Takehiro Yamaguchi; Yoshitaka Tateishi; Yuriko Ozeki; Masaaki Nameta; Tomohiro Kon; Shaban A Kaboso; Naoya Ohara; Olga V Peryanova; Sohkichi Matsumoto
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

8.  Hypoxic Non-replicating Persistent Mycobacterium tuberculosis Develops Thickened Outer Layer That Helps in Restricting Rifampicin Entry.

Authors:  Kishor Jakkala; Parthasarathi Ajitkumar
Journal:  Front Microbiol       Date:  2019-10-11       Impact factor: 5.640

Review 9.  Targeting dormant bacilli to fight tuberculosis.

Authors:  Lanfranco Fattorini; Giovanni Piccaro; Alessandro Mustazzolu; Federico Giannoni
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-11-19       Impact factor: 2.576
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.